摘要血管内皮生长因子(VEGF)是眼内新生血管形成过程中起关键作用的中心环节,抗VEGF治疗是眼内新生血管性疾病治疗的突破点.抗新生血管药物玻璃体腔注入是一种安全、有效的治疗眼部新生血管性及渗出性疾病的方式,具有生物相容性好,价格低,玻璃体内半衰期较长,不需要频繁注射等优点;但目前缺乏多中心研究,其长期效果和安全性有待进一步临床验证.新生血管的病因、类型不同,治疗反应也不一样;同样的新生血管,治疗方式也不尽相同,需要正确理解新生血管性疾病的发病机制,合理选择治疗方式,努力探索安全、有效、经济、方便的治疗新方法.

abstractsUp-regulation of vascular endothelial growth factor(VEGF)is demonstrated to be a key role in formation process of intraocular neovascularization.Anti-VEGF treatment is the breakthrough of intraocular neovascular diseases therapy.Intravitreal injection of anti-neovascularization drug looks to be an effective method on ocular neovascular diseases which with the advantages of good biocompatibility,low prices and longer intravitreal half-time etc.However,at present,it lack of multi-center study;the long-term efficacy and the systematic safety needs the further clinicsl verification.Various types of CNV showed the different therapeutic reactions to either PDT or Anti-VEGF agent,the treatment methods for exudative AMD include laser,PDT,and drug like Triamcinolone Acetonide,several anti-VEGF preparations.Therefore.understanding the pathogenesis of neovascular AMD and choosing a reasonable therapeutic methods are necessary.We should try to explore a safe,effective,economic,new approach.